Now, it has decided to publish a special report on two of GSK's COPD therapies – Breo Ellipta (fluticasone furoate and vilanterol) and Trelegy Ellipta (fluticasone furoate, umeclidinium ...

GSK’s new asthma drug Relvar Ellipta has shown itself to be superior to existing treatments in a major real world trial, the Salford Lung Study (SLS). Developed with US respiratory specialist ...

Teva Pharmaceutical Industries Ltd. ADR 1.42% $19.56B ...

with Trelegy maintaining its position as the number one brand in asthma and COPD globally, management says. Where GSK took a palpable however was within the vaccines division, where revenues fell ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma ... auto-injector device in India. It launched Trelegy Ellipta, the countrys first single inhaler ...

As on 30-06-2024, the company has a total of 16.94 Crore shares outstanding.GSK Pharma Share Price Today is Rs. 2278.60 as on 16 Dec, 2024, 03:31 PM IST. On previous day, the GSK Pharma Share Price ...

GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including respiratory and antiviral, vaccines, over-the-counter (OTC) medicines and health-related ...